Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

A neurotropic herpes simplex virus that was genetically inactivated to prevent replication in normal cells was injected into the brain tumors of 12 patients with tumors that had progressed during previous treatment. Eleven patients had some radiographic or clinical responses, with inflammation detec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-04, Vol.384 (17), p.1613-1622
Hauptverfasser:	Friedman, Gregory K, Johnston, James M, Bag, Asim K, Bernstock, Joshua D, Li, Rong, Aban, Inmaculada, Kachurak, Kara, Nan, Li, Kang, Kyung-Don, Totsch, Stacie, Schlappi, Charles, Martin, Allison M, Pastakia, Devang, McNall-Knapp, Rene, Farouk Sait, Sameer, Khakoo, Yasmin, Karajannis, Matthias A, Woodling, Karina, Palmer, Joshua D, Osorio, Diana S, Leonard, Jeffrey, Abdelbaki, Mohamed S, Madan-Swain, Avi, Atkinson, T. Prescott, Whitley, Richard J, Fiveash, John B, Markert, James M, Gillespie, G. Yancey
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescents Adverse events Biopsy Brain cancer Brain Neoplasms - diagnostic imaging Brain Neoplasms - pathology Brain Neoplasms - radiotherapy Brain Neoplasms - therapy Brain tumors Catheters Chemotherapy Child Child, Preschool Children Clinical trials Combined Modality Therapy Conjunctiva Drug dosages Female Genetic engineering Glioma Glioma - diagnostic imaging Glioma - pathology Glioma - radiotherapy Glioma - therapy Herpes simplex Herpes viruses Humans Immunotherapy Kaplan-Meier Estimate Killer Cells, Natural Kinases Leukocyte Count Lymphocytes Male Oncolysis Oncolytic Virotherapy - adverse effects Patients Pediatrics Polymerase chain reaction Saliva T-Lymphocytes Teenagers Tumor-infiltrating lymphocytes Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A neurotropic herpes simplex virus that was genetically inactivated to prevent replication in normal cells was injected into the brain tumors of 12 patients with tumors that had progressed during previous treatment. Eleven patients had some radiographic or clinical responses, with inflammation detected in some PET scans. The median survival was 12.2 months, and 4 of 11 patients were still alive 18 months after treatment.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2024947